Key Points Several trials failed to demonstrate the efficacy of plaque modification device in patients with severely calcified coronary lesions. Safety and efficacy of the Diamondback 360® Coronary OAS have been demonstrated by the ORBIT II trial. The 2‐year follow‐up of the ORBIT II trial extends the favorable results previously shown at 30‐day and 1‐year follow‐up. The single arm, non‐randomized character of the trial with indirect historical comparison may restrict the results to hypothesis generating and entail further prospective randomized trials.
Yohei Sotomi, Rafael Cavalcante, Richard Shlofmitz, Pannipa Suwannasom, Hiroki Tateishi, Erhan Tenekecioğlu, Yaping Zheng, Mohammad Abdelghani, Robbert de Winter, Joanna J. Wykrzykowska, Yoshinobu Onuma, Patrick W. Serruys
Yaping Zeng, Hiroki Tateishi, Rafael Cavalcante, Erhan Tenekecioğlu, Pannipa Suwannasom, Yohei Sotomi, Carlos Collet, Shaoping Nie, Hans Jonker, Jouke Dijkstra, Maria Radu, Lorenz Räber, Dougal R. McClean, Robert‐Jan van Geuns, Evald Høj Christiansen, Therese Fahrni, Jacques Koolen, Yoshinobu Onuma, Nico Bruining, Patrick W. Serruys
Javier Escaned, Adrian Banning, Vasim Farooq, Mauro Echavarría‐Pinto, Yoshinobu Onuma, Nicola Ryan, Rafael Cavalcante, Carlos M. Campos, Bojan Stanetić, Yuki Ishibashi, Pannipa Suwannasom, A. Pieter Kappetein, David Taggart, Marie‐Angèle Morel, Gerrit‐Anne van Es, Patrick W. Serruys
Discussion(0)
No comments yet. Be the first to comment.